Integrated safety analysis: Frequency of urinary tract infections in patients with psoriasis treated with ixekizumab - 19/06/20
![](/templates/common/images/mail.png)
Funding sources: This study was sponsored by Eli Lilly and Company. |
|
Conflicts of interest: Dr Smith has been an advisor for and/or received speaking fees and/or served as an investigator in clinical trials for AbbVie, Amgen, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Janssen Cilag, Novartis, Pfizer, Sanofi Genzyme, and UCB. Dr Conrad has served as a scientific adviser and/or clinical study investigator and/or paid speaker for AbbVie, Actelion, Amgen, BMS, Celgene, Galderma, Incyte, Janssen, LEO Pharma, Eli Lilly and Company, MSD, Novartis, and Pfizer. Dr Gottlieb discloses current consulting/advisory board agreements with Janssen Inc, Celgene Corp, Beiersdorf, Bristol Myers Squibb Co, AbbVie, UCB, Novartis, Incyte, Eli Lilly and Company, Sun Pharmaceutical Industries, Xbiotech, LEO Pharma, Avotres Therapeutics, and Boehringer Ingelheim. Drs Patel, Xu, Riedl, and Schuster are employees of and may own stock in Eli Lilly and Company. Dr Ramharter has no conflicts of interest to declare. |
|
IRB approval status: IRB approval was obtained for all of the individual studies included in this analysis. |
|
Reprints not available from the authors. |
Vol 83 - N° 1
P. 261-263 - juillet 2020 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?